Brain-Derived Neurotrophic Factor in Pediatric Acquired Brain Injury and Recovery.
Amery Treble-BarnaBailey A PetersenZachary StecYvette P ConleyEricka L FinkPatrick M KochanekPublished in: Biomolecules (2024)
We review emerging preclinical and clinical evidence regarding brain-derived neurotrophic factor (BDNF) protein, genotype, and DNA methylation (DNAm) as biomarkers of outcomes in three important etiologies of pediatric acquired brain injury (ABI), traumatic brain injury, global cerebral ischemia, and stroke. We also summarize evidence suggesting that BDNF is (1) involved in the biological embedding of the psychosocial environment, (2) responsive to rehabilitative therapies, and (3) potentially modifiable. BDNF's unique potential as a biomarker of neuroplasticity and neural repair that is reflective of and responsive to both pre- and post-injury environmental influences separates it from traditional protein biomarkers of structural brain injury with exciting potential to advance pediatric ABI management by increasing the accuracy of prognostic tools and informing clinical decision making through the monitoring of therapeutic effects.
Keyphrases
- brain injury
- cerebral ischemia
- subarachnoid hemorrhage
- traumatic brain injury
- dna methylation
- decision making
- stress induced
- gene expression
- human health
- cancer therapy
- protein protein
- mental health
- atrial fibrillation
- binding protein
- risk assessment
- type diabetes
- adipose tissue
- metabolic syndrome
- amino acid
- climate change
- small molecule
- drug delivery
- nk cells
- insulin resistance
- copy number
- cell therapy